Comparative Effects of Substituted Amphetamines (PMA, MDMA, and METH) on Monoamines in Rat Caudate
B. Gough, Syed Z. Imam, Bruce E. Blough, William Slikker, Syed F. Ali
Annals of the New York Academy of Sciences June 1, 2002 DOI: 10.1111/j.1749-6632.2002.tb04182.x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | PMA MDMA METH |
| Dose | 2.5, 5, 10, 20 mg/kg (PMA); 10 and 20 mg/kg (MDMA); 2.5 mg/kg (METH) |
| Duration | 4 hours |
| Topics | MDMA Serotonin |
| Keywords | Homovanillic acid Microdialysis Dopamine Meth- Monoamine neurotransmitter Extracellular Neurotoxicity Pharmacology 3,4-dihydroxyphenylacetic acid Endocrinology |
| Citations | 47 |
| Key findings | PMA, like MDMA and METH, is capable of producing dopaminergic and serotonergic neurotoxicity in rats. |
Abstract
A bstract : Paramethoxyamphetamine (PMA) is a methoxylated phenethylamine derivative that has been used illicitly in Australia since 1994. PMA is also becoming popular at rave parties in the United States. PMA raised concern when a series of fatalities resulted after its use in South Australia, where it was marketed as “ecstasy,” which is the colloquial name for MDMA. In the present study, we evaluated the comparative neurotoxicity of substituted amphetamines in rats. Extracellular levels of dopamine (DA), 3,4‐dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5‐HT), and 5‐hydroxyindoleacetic acid (5‐HIAA) were assayed in the caudate of freely moving rats using microdialysis and HPLC‐EC. Dialysates were assayed every 20 minutes for 4 hours after an intraperitoneal (i.p.) injection of PMA (2.5, 5, 10, 20 mg/kg), MDMA (10 and 20 mg/kg), or METH (2.5 mg/kg). METH produced a significant increase in extracellular DA (700%), and significant decreases in extracellular DOPAC and HVA (30% and 50%), with no detectable changes in either 5‐HT or 5‐HIAA. MDMA produced significant increases in DA (700% at 10 mg/kg and 950% at 20 mg/kg) and decreases in DOPAC (15% for both 10 and 20 mg/kg), and HVA (50% at 10 mg/kg and 35% at 20 mg/kg). MDMA also increased 5‐HT (350% at 10, and 575% at 20 mg/kg), and decreased 5‐HIAA to 60% for both dose levels. PMA produced no detectable increases in DA at dose levels of 2.5, 5, or 10 mg/kg, but significantly increased DA (975%) at a dose of 20 mg/kg. However, PMA significantly decreased DOPAC at all dose levels (75% at 2.5; 40% at 5; 30% at 10; 10% at 20 mg/kg), with comparable decreases in HVA at all dose levels. PMA also produced significant increases in 5‐HT at 10 and 20 mg/kg (350% for both dose levels), with no detectable changes in 5‐HT at 2.5 or 5 mg/kg. All dose levels of PMA significantly decreased 5‐HIAA (50 to 70%). These data suggest that PMA, like MDMA and METH, is capable of producing dopaminergic and serotonergic neurotoxicity.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 9
- Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA) Journal of Neuroscience November 23, 2011
- MDMA‐evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain Synapse July 14, 2004
- Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature Drug and Alcohol Review July 1, 2005
- Effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide Brain Research March 8, 2005
- Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders. Metabolomics : Official journal of the Metabolomic Society August 2, 2023
and 4 more in the library
Cites 7
- Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes Journal of Medicinal Chemistry May 1, 1982
- Fatalities Caused by the MDMA-Related Drug Paramethoxyamphetamine (PMA) Journal of Analytical Toxicology October 1, 2001
- The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews September 2003
- 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neuroscience and biobehavioral reviews March 1999
- Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology June 1995
and 2 more in the library